[2] Dulaglutide (Trulicity), another once-weekly injectable GLP-1 agonist, demonstrates a somewhat more favourable gastrointestinal tolerability profile in some studies, with nausea reported in approximately 8-12% of patients at lower doses, though rates increase with higher doses (3
GI effects are the primary concern, primarily nausea, vomiting, diarrhea, and constipation
Lipogenesis Metabolism Besides an increased metabolic rate, MCFAs are associated with increased lipogenesis in the liver (74, 75)
Pregnant or breastfeeding individuals should seek medical guidance
And can it actually help you lose weight
You get protein, fiber, and wholesome carbohydrates all in a single bowl